通络生骨胶囊通过上调VEGF信号通路促进血管生成改善激素性股骨头坏死
通络生骨胶囊(TLSGC)是临床用于激素性股骨头坏死(GIONFH)的中成药。本研究通过LC-MS鉴定33种化学成分,构建药物-疾病靶点网络筛选122个核心基因,并在甲基泼尼松龙诱导的大鼠模型和地塞米松抑制的HUVECs中验证。结果表明TLSGC通过上调VEGF-VEGFR2-PKC-Raf-1-MEK-ERK信号轴促进血管生成,从而改善GIONFH。
要点
- TLSGC含33种化学成分,网络分析提示VEGF通路为核心靶点。
- TLSGC可改善大鼠GIONFH的影像与病理,并保护血管功能。
- 机制为上调VEGF-VEGFR2-PKC-Raf-1-MEK-ERK轴促血管生成。
核心结论
- TLSGC通过上调VEGF-VEGFR2-PKC-Raf-1-MEK-ERK信号轴促进血管生成,对GIONFH发挥明显疗效。
研究设计与样本
- 研究采用LC-MS表征TLSGC化学成分,结合MedChem Studio软件与既往GIONFH相关基因构建药物-疾病靶点网络,并通过拓扑参数筛选候选靶点。
- 实验验证采用甲基泼尼松龙诱导的大鼠模型和地塞米松抑制的人脐静脉内皮细胞(HUVECs)。
主要发现
- TLSGC中表征出33种化学成分,基于这些成分与GIONFH相关基因筛选出122个核心基因。
- 核心基因在VEGF通路的VEGF-VEGFR2-PKC-Raf1-MEK-ERK信号轴上富集程度最高。
- TLSGC在大鼠中经micro-CT和病理检查证实对GIONFH的治疗作用,并通过血管造影、CD31免疫组化、体内血管功能指标、离体主动脉环实验及HUVECs迁移、侵袭和成管实验证实对血管损伤的保护作用。
- TLSGC在体内外有效抑制VEGF、VEGFR2及其下游靶点Raf-1、PKC、p-MEK和p-ERK蛋白的下调。
临床怎么用
- 对于激素性股骨头坏死患者,可考虑在规范治疗基础上联合通络生骨胶囊,以改善血管损伤和骨坏死。
- 临床决策需结合患者具体情况,本研究的实验证据支持其促血管生成机制,但需进一步临床验证。
局限性
- 研究主要基于动物模型和体外细胞实验,缺乏临床随机对照试验证据。
- TLSGC的活性成分及其直接作用靶点尚未完全明确,需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Tongluo Shenggu Capsule (TLSGC) is a product of Traditional Chinese patent medicine that has been effective in glucocorticoid-induced osteonecrosis of the femoral head (GIONFH) clinically for many years. It is made from water extracts of a well-used herbal and dietary supplement-pigeon pea leaves. Nevertheless, the material basis and pharmacological mechanisms of TLSGC ameliorating GIONFH needed to be better defined. PURPOSE: To investigate the material basis and pharmacological mechanisms of TLSGC to ameliorate GIONFH. METHODS: The chemical compositions in TLSGC were characterized using the LC-MS system. Based on integrating the relevant targets of TLSGC in MedChem Studio software and GIONFH-related genes in our previous work, a "drug targets-disease genes" interaction network was constructed. The candidate targets of TLSGC ameliorating GIONFH were filtrated by topological characteristic parameters and further experimental validated based on methylprednisolone-induced rat model and dexamethasone-inhibited human umbilical vein endothelial cells (HUVECs). RESULTS: A total of 33 chemical compositions were characterized in TLSGC. Based on these compositions and GIONFH-related genes, 122 hub genes were selected according to topological parameters calculation. Biological functions were mainly enriched in four over-expressed modules of vascular damage, inflammation and apoptosis, bone metabolism and energy metabolism. The hub genes had the maximum enrichment degree in the VEGF-VEGFR2-PKC-Raf1-MEK-ERK signaling axis of the VEGF pathway. Experimentally, the therapeutic effects of TLSGC against GIONFH in rats were proved by micro-CT and pathological examination. Then, the protective effects of TLSGC on vascular damage were determined using angiography, CD31 immunohistochemistry, vascular function indicators in vivo, aortic ring test ex vivo, and the HUVECs activities in vitro including migration, invasion and tube formation. Mechanically, TLSGC effectively suppressed the downregulation of VEGF and VEGFR2 and their downstream targets, including Raf-1, PKC, p-MEK, and p-ERK proteins both in vivo and in vitro. CONCLUSION: TLSGC could promote angiogenesis by upregulating the VEGF-VEGFR2-PKC-Raf-1-MEK-ERK signaling axis, thereby exerting an apparent curative effect on GIONFH.
引用
- Yang C, Wang J, Chen L, et al. Tongluo Shenggu capsule promotes angiogenesis to ameliorate glucocorticoid-induced femoral head necrosis via upregulating VEGF signaling pathway. Phytomedicine. 2022. PMID: 36608500. doi:10.1016/j.phymed.2022.154629
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。